Literature DB >> 1093649

Trimethorpim-sulfamethoxazole in the treatment of chronic prostatitis.

D Dow.   

Abstract

Chronic prostatis is a common condition for which evidence of bacterial etiology is often lacking, possibly because of difficulty in obtaining secretion from the diseased portion of the gland. Aids to diagnosis apart from bacteriologic studies are of little value. It has been shown that trimethoprim reaches high levels in the prostatic fluid and when combined with sulfamethoxazole provides a highly effective antibacterial agent. In a survey of 40 patients with chronic prostatitis treated with TMP-SMX the usefulness of the combination was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1093649      PMCID: PMC1956466     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  5 in total

1.  Prostatitis. Observations on activity of trimethoprim-sulfamethoxazole in the prostate.

Authors:  E M Meares
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

2.  Use of trimethoprim-sulfamethoxazole in chronic prostatitis.

Authors:  A E Chesley; D Dow
Journal:  Urology       Date:  1973-09       Impact factor: 2.649

3.  Anatomical factors in prostatitis.

Authors:  N J Blacklock
Journal:  Br J Urol       Date:  1974-02

4.  Diffusion of antibiotics from plasma into prostatic fluid.

Authors:  D G Winningham; N J Nemoy; T A Stamey
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

5.  Bacteriologic localization patterns in bacterial prostatitis and urethritis.

Authors:  E M Meares; T A Stamey
Journal:  Invest Urol       Date:  1968-03
  5 in total
  2 in total

Review 1.  Diagnostic and therapeutic problems in prostatitis. Therapeutic position of ofloxacin.

Authors:  J Aagaard; P O Madsen
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 2.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.